{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Anemia (>= Grade 3 or 4)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Hypertension (>= Grade 3 or 4)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"}],"units":"Participants"}],"description":"Hematologic and non-hematologic toxicities will be graded. The new international criteria proposed by the Response Evaluation Criteria In Solid Tumors (RECIST) will serve as the guideline.\n\nOn Day 1 of each cycle (4 weeks) for the duration of treatment and then 30 days following the last treatment","groups":[{"description":"Carfilzomib is administered twice-weekly on consecutive days (days 1, 2, 8, 9, 15, 16) as a 30-minute intravenous infusion for 3 weeks every 4 weeks (1 cycle) with dexamethasone given as pre-medication. The dose of carfilzomib is 20 mg/m2 on days 1 and 2 of cycle 1 and is then escalated in succeeding weeks and cycles to 56 mg/m2 if no dose limiting toxicities occur. Acyclovir is given orally at 400 mg twice daily during therapy but may be discontinued at some point. Therapy will continue until side effects become unacceptable, the disease progresses, or the doctor withdraws the patient.\n\nCarfilzomib: Carfilzomib will be administered on days 1, 2, 8, 9, 15, 16 within each 4 week cycle.\n\nDexamethasone: Administered prior to administration of Study drug\n\nAcyclovir: Administered orally twice daily","id":"OG000","title":"Carfilzomib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All serious adverse events and \\> grade 3 toxicities were reported for patients who received treatment with Carfilzomib","reportingStatus":"POSTED","timeFrame":"Baseline through 36 months","title":"Assessment of Toxicities","type":"SECONDARY","unitOfMeasure":"Participants"}